While the VITATOPS trial does not provide sufficiently robust evidence in support of B vitamin supplementation for secondary prevention of vascular events after stroke or TIA, there is still a place for further trials of homocysteine-lowering treatment.
PETER SANDERCOCK, M.D., is with the department of clinical neurosciences, Western General Hospital, Edinburgh. His comments are paraphrased from an editorial (Lancet Neurology 2010 Aug 4 [doi:10.1016/S1474-4422(10)70188-5]). He reported that he has no conflicts of interest.